Evaluation of serum levels of sCD30L ligand in patients with ovarian cancer in terms of selected clinico-pathological factors

Abstract

Aim of the studyThe CD30L ligand is a membrane-associated glycoprotein expressed by activated CD4+Th cells, macrophages, dendritic cells, and B lymphocytes. It binds to the CD30 receptor carried on activated and helper Th cells, inducing the immune response and apoptosis. The aim of this retrospective study was to determine the level of sCD30L in the serum of patients at diagnosis of ovarian cancer and at relapse and to assess the potential association of this ligand with selected clinico-pathologic factors.Material and methodsWe studied 69 patients with ovarian cancer allocated to two groups: A – ovarian cancer at diagnosis, B – relapse of ovarian cancer and active growth of the tumor.ResultsWe found high levels of sCD30L in ovarian cancer patients. Levels at relapse (21.48 ng/ml) were significantly higher than at diagnosis (11.81 ng/ml). Poor response to first-line chemotherapy was accompanied by higher levels of sCD30L and by several other findings: resistance to platinum analogs was common, neoadjuvant chemotherapy was needed, relapse and death during two-year follow-up were frequent.ConclusionsOur present study might initially suggest that elevated concentration of sCD30L can be an important finding prognosticating a poor prognosis and is associated with platinum resistant and refractory cases of ovarian cancer. However, studies are needed on larger groups of patients.

Nanoscale Drug Delivery Platforms Overcome Platinum-Based Resistance in Cancer Cells Due to Abnormal Membrane Protein Trafficking

“…128–130 In other cases, bio-nanoparticles, such as antibody, peptides, etc., showed their ability to induce immune response and apoptosis. 131 In recent years, several nanoscale drug carriers are currently in clinical trials. 132 For instance, cisplatin results in severe kidney toxicity, requiring patients to drink large amounts of water during treatment.…”

“…A 15 kDa variable domain of camelid heavy-chain-only antibodies, called Nanobodies, are being explored for their ability to potentiate cancer therapy. − In other cases, bionanoparticles, such as antibodies peptides, etc. , showed their ability to induce immune response and apoptosis . In recent years, several nanoscale drug carriers have entered clinical trials .…”